2025 / 06

Next Paper
DOI: 10.24075/brsmu.2025.034
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Perivascular mast cells and angiogenesis in the tumor microenvironment of synovial sarcoma

Bulanov DV1,2, Makhachev DR1, Suntsov MA1, Gubich DS1, Filippova YD1, Krutilina AA1, Svoyak AV1, Ivannikova AA1, Ghabibullaev RM3
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Priorov National Medical Research Center of Traumatology and Orthopedics, Moscow, Russia

3 Dedov Endocrinology Research Centre, Moscow, Russia

Correspondence should be addressed: Dalgat R. Makhachev
Akademika Volgina, 37, Moscow, 117437, Russia; ur.liam@2002taglad

About paper

Author contribution: Bulanov DV — study supervision, design, and conceptualization, article editing; Makhachev DR, Suntsov MA, Gubich DS — data analysis and interpretation, article authoring, editing; Filippova YuD, Krutilina AA, Ghabibullaev RM, Svoyak AV, Ivannikova AI — collection of the clinical data, article editing.

Received: 2025-10-07 Accepted: 2025-11-05 Published online: 2025-11-21
|
  1. Fiore M, Sambri A, Spinnato P, et al. The biology of synovial sarcoma: state-of-the-art and future perspectives. Curr Treat Options Oncol. 2021; 22 (12): 109. DOI: 10.1007/s11864-021-00914-4.
  2. Gazendam AM, Popovic S, Munir S, et al. Synovial sarcoma: a clinical review. Curr Oncol. 2021; 28 (3): 1909–20. DOI: 10.3390/curroncol28030177.
  3. Ribatti D. Tryptase and tumor angiogenesis. Front Oncol. 2024; 14: 1500482. DOI: 10.3389/fonc.2024.1500482.
  4. Ammendola M, Gadaleta CD, Patruno R, et al. Mast cells positive for c-Kit receptor and tryptase correlate with angiogenesis in cancerous and adjacent normal pancreatic tissue. Cells. 2021; 10 (2): 444. DOI: 10.3390/cells10020444.
  5. Segura-Villalobos D, Bazany-Rosenzweig NR, Mayoral RJ, et al. Mast cell–tumor interactions: molecular mechanisms and clinical perspectives. Cells. 2022; 11 (3): 349. DOI: 10.3390/cells11030349.
  6. Liu Z, Wang L, Wang J, et al. Angiogenic signaling pathways and anti-angiogenic therapy. Signal Transduct Target Ther. 2023; 8: 227. DOI: 10.1038/s41392-023-01460-1.
  7. Panagi M, Lesuy Y, Tosti R, et al. Stabilizing tumor-resident mast cells restores T-cell infiltration in sarcomas and potentiates PD-L1 inhibition. Clin Cancer Res. 2024; 30 (11): 2582–97. DOI: 10.1158/1078-0432.CCR-24-0246.
  8. Toulmonde M, Guégan J-P, Spalato-Ceruso M, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab. Signal Transduct Target Ther. 2025; 10: 202. DOI: 10.1038/s41392-025-02278-9.
  9. Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023; 4 (1): 9–26. DOI: 10.1038/s43018-022-00473-z.
  10. Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, et al. Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers. Nat Cancer. 2024; 5 (7): 1102– 20. DOI: 10.1038/s43018-024-00754-9.
  11. Luk S, Chokshi PR, Torres-Rodriguez I, et al. Immunological differences between monophasic and biphasic synovial sarcoma. Cancer Immunol Immunother. 2024; 74 (1): 31. DOI: 10.1007/s00262-024-03868-2.
  12. Wisdom AJ, Mowery YM, Hong CS, et al. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nat Commun. 2020; 11: 6410. DOI: 10.1038/s41467-020-19917-0.
  13. Medina-Ceballos E, Liotta A, Ali S, et al. The prognostic impact of the tumor immune microenvironment in synovial sarcoma: an immunohistochemical analysis using digital pathology and conventional scoring. J Pers Med. 2025; 15 (5): 169. DOI: 10.3390/jpm15050169.
  14. Giner F, Medina-Ceballos E, López-Reig R, et al. The combined immunohistochemical expression of GLI1 and BCOR in synovial sarcomas for the identification of three risk groups and their prognostic outcomes: a study of 52 patients. Int J Mol Sci. 2024; 25 (14): 7615. DOI: 10.3390/ijms25147615.
  15. Recine F, Piciucchi S, De Vincenzo F, et al. Clinical and translational implications of immunotherapy in soft tissue and bone sarcomas. Front Immunol. 2024; 15: 1378398. DOI: 10.3389/fimmu.2024.1378398.
  16. Subramanian A, Caswell DR, Wang H, et al. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. Nat Cancer. 2024; 5 (4): 642–58. DOI: 10.1038/s43018-024-00743-y.
  17. West PW, Bulfone-Paus S. Mast cell tissue heterogeneity and specificity of immune cell recruitment. Front Immunol. 2022; 13: 932090. DOI: 10.3389/fimmu.2022.932090.
  18. Spalato-Ceruso M, Valverde P, Italiano A. New strategies in soft tissue sarcoma treatment. J Hematol Oncol. 2024; 17 (1): 76. DOI: 10.1186/s13045-024-01580-3.
  19. Lichterman JN, Reddy SM. Mast Cells: A New Frontier for Cancer Immunotherapy. Cells. 2021; 10 (6): 1270. DOI: 10.3390/cells10061270.
  20. Ribatti D. New insights into the role of mast cells as a therapeutic target in cancer through the blockade of immune checkpoint inhibitors. Front Med (Lausanne). 2024; 11: 1373230. DOI: 10.3389/fmed.2024.1373230.